Vincentage Pharma, a Chengdu-based metabolic disease company, reported that VCT220, its oral small-molecule GLP-1 receptor agonist, produced mean body weight reductions of approximately 12% over 52 weeks in obese or overweight Chinese adults, clearing placebo by a wide margin and positioning the company to file for regulatory approval in China.
VCT220 Phase 3 trial results at a glance
The pivotal Phase III trial (NCT06939296) is a multicenter, randomized, double-blind, placebo-controlled study that enrolled 840 adults in China with obesity (BMI ≥28 kg/m²) or overweight (24 kg/m² ≤ BMI <28 kg/m²) with at least one weight-related comorbidity. Participants were randomized 1:1:1 to receive VCT220 120 mg, VCT220 160 mg, or placebo once daily for 52 weeks. The trial was initiated in November 2024.
Key efficacy and safety findings
At 52 weeks, participants in the 120 mg group achieved a mean body weight reduction of 12.2%, and those in the 160 mg group achieved 12.4%, compared with 1.3% in the placebo group. Both active doses met the primary endpoint with statistical significance. The two dose levels produced closely similar results, suggesting the dose-response curve may be relatively flat between 120 mg and 160 mg, though the company has not yet disclosed whether the difference between doses was statistically meaningful.
Safety findings were consistent with the established profile of the GLP-1 receptor agonist class. Gastrointestinal adverse events were the most commonly reported, generally mild to moderate in severity, and concentrated during the dose-escalation period before subsiding during maintenance. No severe nausea or vomiting events were reported. Discontinuation rates due to treatment-related adverse events were 1.8% in each active arm, and no hepatic safety signal was identified.
What the data mean for VCT220 obesity treatment positioning
VCT220's primary differentiating feature is its oral, non-peptide small-molecule format. All GLP-1 receptor agonists currently approved in China for weight management — including semaglutide, liraglutide, beinaglutide, mazdutide, and ecnoglutide — require subcutaneous injection. Orlistat, the only oral approved option, operates through a different mechanism and produces substantially more modest weight reduction. An oral GLP-1 receptor agonist that achieves double-digit percentage weight loss could address a meaningful gap in the China obesity treatment landscape, particularly given documented adherence challenges associated with injectable therapies.
The compound is designed for once-daily administration without food or water restrictions, does not require refrigeration or light-protected storage, and has a titration period as short as six weeks. These characteristics distinguish it from Novo Nordisk's Rybelsus (oral semaglutide), which requires fasting administration and specific timing constraints, and from the injectable agents that dominate the current GLP-1 receptor agonist weight management market in China.